User profiles for J. Fukuoka
Prof. Junya Fukuoka, MD. PhD.Dept of Pathology Informatics, Nagasaki University / Dept of Pathology, Kameda Medical … Verified email at nagasaki-u.ac.jp Cited by 11929 |
Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report
Acute exacerbation of idiopathic pulmonary fibrosis has been defined as an acute, clinically
significant, respiratory deterioration of unidentifiable cause. The objective of this …
significant, respiratory deterioration of unidentifiable cause. The objective of this …
Imaging of pulmonary emphysema: a pictorial review
M Takahashi, J Fukuoka, N Nitta… - … journal of chronic …, 2008 - Taylor & Francis
The term ‘emphysema’ is generally used in a morphological sense, and therefore imaging
modalities have an important role in diagnosing this disease. In particular, high resolution …
modalities have an important role in diagnosing this disease. In particular, high resolution …
Peribronchiolar metaplasia: a common histologic lesion in diffuse lung disease and a rare cause of interstitial lung disease: clinicopathologic features of 15 cases
Peribronchiolar metaplasia (PBM) is a histologic lesion consisting of peribronchiolar metaplasia
(PBM) of bronchiolar-type epithelium. Although widely recognized, PBM has received …
(PBM) of bronchiolar-type epithelium. Although widely recognized, PBM has received …
[HTML][HTML] Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival
Background Tobacco smoking is responsible for over 90% of lung cancer cases, and yet the
precise molecular alterations induced by smoking in lung that develop into cancer and …
precise molecular alterations induced by smoking in lung that develop into cancer and …
Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore
…, E Selbs, CPL Mcevoy, CDL Hayden, J Fukuoka… - Human pathology, 2003 - Elsevier
Severe acute respiratory syndrome (SARS) is an infectious condition caused by the SARS-associated
coronavirus (SARS-CoV), a new member in the family Coronaviridae. To evaluate …
coronavirus (SARS-CoV), a new member in the family Coronaviridae. To evaluate …
[HTML][HTML] Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study
…, S Pomplun, H Taniguchi, J Fukuoka… - The lancet Respiratory …, 2016 - thelancet.com
Background Diffuse parenchymal lung disease represents a diverse and challenging group
of pulmonary disorders. A consistent diagnostic approach to diffuse parenchymal lung …
of pulmonary disorders. A consistent diagnostic approach to diffuse parenchymal lung …
[HTML][HTML] Early immune-related adverse events and association with outcome in advanced non–small cell lung cancer patients treated with nivolumab: a prospective …
…, K Uehara, Y Imai, K Ishida, J Fukuoka… - Journal of Thoracic …, 2017 - Elsevier
Introduction Retrospective studies have shown immune-related adverse events (irAEs) to
be associated with better prognosis. However, no prospective clinical trials have been …
be associated with better prognosis. However, no prospective clinical trials have been …
[HTML][HTML] Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients
…, H Kitano, C Perry, J Hanaoka, J Fukuoka… - Journal of translational …, 2020 - Springer
Background The tumor microenvironment (TME) is a critical player in tumor progression,
metastasis and therapy outcomes. Tumor-associated macrophages (TAMs) are a well-…
metastasis and therapy outcomes. Tumor-associated macrophages (TAMs) are a well-…
Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of …
…, J Fukuoka, SS Shen, J Jagirdar - … of pathology & …, 2012 - meridian.allenpress.com
Context.—Differentiation of non–small cell carcinoma into histologic types is important because
of new, successful therapies that target lung adenocarcinoma (ACA). TTF-1 is a favored …
of new, successful therapies that target lung adenocarcinoma (ACA). TTF-1 is a favored …
[HTML][HTML] Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West …
The purpose of this study was to evaluate the efficacy of gefitinib and the feasibility of
screening for epidermal growth factor receptor (EGFR) mutations among select patients with …
screening for epidermal growth factor receptor (EGFR) mutations among select patients with …